Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...
After witnessing my father’s tortuous battle with the illness I wanted to understand my own risk, so I visited a brain expert ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...
Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding ...
FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...
FDA fast-tracks novel Parkinson’s cell therapy NouvNeu001, advancing treatment for dopaminergic neuron loss and motor ...
Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that it’s not ...
ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company focused on the ...
ABLi Therapeutics ("ABLi"), a biotechnology company developing therapeutics to address diseases that are associated with activation of Abelson Tyrosine Kinases (c-Abl kinases), announces it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results